Even if we compared PlGF levels in patients with similar renal and clinical conditions (HUS and MHT), future studies should aim to compare PlGF in SSc-SRC+ patients who do not fulfill Butler et al classification criteria,13 particularly in case of normotensive presentation. This evidence concerns the gene PGF and malignant hypertension.